Premium
Combination chemotherapy with aclarubicin in metastatic breast cancer
Author(s) -
Simader H.,
Hausmaninger H.,
Fereberger W.,
Samonigg H.
Publication year - 1987
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1987.tb00027.x
Subject(s) - aclarubicin , medicine , cyclophosphamide , regimen , vincristine , breast cancer , chemotherapy , metastatic breast cancer , cancer , oncology , gastroenterology , surgery , doxorubicin
SUMMARY Twenty‐eight women with advanced breast cancer were treated with aclarubicin, vincristine and cyclophosphamide. Aclarubicin was given to 16 patients in a two days regimen (40 mg/m 2 i.v. day 1 + 2). Five of these patients experienced severe gastrointestinal toxicity and refused further therapy. Therefore aclarubicin was administered in a four days regimen (20 mg/m 2 i.v. day 1–4) to another 12 patients. The overall response rate was 31% with 9% of the patients having a complete remission. This objective response is higher than that achieved when aclarubicin is given alone. Our study confirms experimental data suggesting synergism of aclarubicin, vincristine and cyclophosphamide.